Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026
17 Apr 2026 - 21 Apr 2026

Rapid Test for Sepsis-Related Pathogens Being Developed

By LabMedica International staff writers
Posted on 20 Oct 2009
A rapid assay for sepsis-related pathogens will provide results in less than two hours. More...
The fast access to information will enable physicians to quickly prescribe a specific course of treatment, thereby improving patient outcomes.

Smiths Detection (Watford, UK) received a $1 million, two-year grant from the National Institute of Biomedical Imaging and Bioengineering (NIBIB; Bethesda, MD, USA) to develop a rapid test for eight microorganisms that commonly cause burn/wound infections leading to septicemia (blood-poisoning).

The test will run on Smiths Detection's clinical Bio-Seeq system, designed to be used at point of care (POC) in critical care settings. With Bio-Seeq, the sample is introduced into a disposable cartridge, which is then placed on the instrument. The system should require no specialized molecular biology training.

Development of the highly multiplexed test will be achieved by using Smiths Detection's linear-after-the-exponential-polymerase chain reaction (LATE-PCR) nucleic acid amplification and detection technology. This technology was licensed from Brandeis University (Waltham, MA, USA), which will also support the project. The test will be suitable for use in a conventional laboratory setting or in a Point-of-Care (POC) setting running on the Bio-Seeq instrument.

Over 750,000 Americans develop sepsis each year. Globally, sepsis affects millions of people and is the leading cause of death in noncoronary Intensive Care Units (ICUs). Patients with more than 20% burn coverage, run a 97% risk of developing a wound infection, and the longer it takes to identify the cause, the higher the risk of full sepsis.

Traditional pathogen detection methods can take up to 72 hours and rapid molecular tests, when performed in a central laboratory, can take up to a day, depending on sample transport and processing times. Validation of the assay under development as well as evaluation of the performance of Bio-Seeq in an ICU setting will be conducted at the University of California (UC) Davis Medical Center (Sacramento, CA, USA).

Smiths Detection diagnostics unit is part of Smiths Group. It develops hardy instruments that are easily operated by specialists in clinical and veterinary procedures.

Related Links:
Smiths Detection
National Institute of Biomedical Imaging and Bioengineering
Brandeis University
University of California Davis Medical Center


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Rapid Molecular Testing Device
FlashDetect Flash10
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.